SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-20-126099
Filing Date
2020-04-29
Accepted
2020-04-29 16:05:56
Documents
6
Period of Report
2020-06-15
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A d852297ddef14a.htm DEF 14A 410126
2 GRAPHIC g852297dsp004.jpg GRAPHIC 8275
3 GRAPHIC g852297dsp043.jpg GRAPHIC 20546
4 GRAPHIC g852297dsp045.jpg GRAPHIC 11015
5 GRAPHIC g852297page009.jpg GRAPHIC 97642
6 GRAPHIC g852297page010.jpg GRAPHIC 121851
  Complete submission text file 0001193125-20-126099.txt   769167
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38871 | Film No.: 20830257
SIC: 2834 Pharmaceutical Preparations